325 related articles for article (PubMed ID: 24605040)
21. Frequency scale symptoms for gastroesophageal reflux disease (Frequency Scale for Symptoms of GERD) predicts need for addition of prokinetics to proton pump inhibitor therapy.
Nandurkar S
J Gastroenterol Hepatol; 2008 Aug; 23(8 Pt 1):1165-7. PubMed ID: 18699977
[No Abstract] [Full Text] [Related]
22. A Systematic Review and Meta-analysis of Randomized Control Trials: Combination Treatment With Proton Pump Inhibitor Plus Prokinetic for Gastroesophageal Reflux Disease.
Jung DH; Huh CW; Lee SK; Park JC; Shin SK; Lee YC
J Neurogastroenterol Motil; 2021 Apr; 27(2):165-175. PubMed ID: 33795539
[TBL] [Abstract][Full Text] [Related]
23. Factors affecting response to proton pump inhibitor therapy in patients with gastroesophageal reflux disease: a multicenter prospective observational study.
Matsuhashi N; Kudo M; Yoshida N; Murakami K; Kato M; Sanuki T; Oshio A; Joh T; Higuchi K; Haruma K; Nakada K
J Gastroenterol; 2015 Dec; 50(12):1173-83. PubMed ID: 25851931
[TBL] [Abstract][Full Text] [Related]
24. Medical treatments of GERD: the old and new.
Vela MF
Gastroenterol Clin North Am; 2014 Mar; 43(1):121-33. PubMed ID: 24503363
[TBL] [Abstract][Full Text] [Related]
25. Proton pump inhibitor monotherapy and the risk of cardiovascular events in patients with gastro-esophageal reflux disease: a meta-analysis.
Sun S; Cui Z; Zhou M; Li R; Li H; Zhang S; Ba Y; Cheng G
Neurogastroenterol Motil; 2017 Feb; 29(2):. PubMed ID: 27577963
[TBL] [Abstract][Full Text] [Related]
26. [Gastroesophageal reflux disease: pathogenetic basis of differentiated tactics of treatment].
Tkachenko EI; Uspenskiĭ IuP; Karateev AE; Bakulin IG; Pakhomova IG
Eksp Klin Gastroenterol; 2009; (2):104-14. PubMed ID: 19552028
[TBL] [Abstract][Full Text] [Related]
27. Proton Pump Inhibitors in Gastroesophageal Reflux Disease: Friend or Foe.
Gyawali CP
Curr Gastroenterol Rep; 2017 Sep; 19(9):46. PubMed ID: 28780717
[TBL] [Abstract][Full Text] [Related]
28. Response of regurgitation to proton pump inhibitor therapy in clinical trials of gastroesophageal reflux disease.
Kahrilas PJ; Howden CW; Hughes N
Am J Gastroenterol; 2011 Aug; 106(8):1419-25; quiz 1426. PubMed ID: 21537361
[TBL] [Abstract][Full Text] [Related]
29. Fixed combination of hyaluronic acid and chondroitin-sulphate oral formulation in a randomized double blind, placebo controlled study for the treatment of symptoms in patients with non-erosive gastroesophageal reflux.
Palmieri B; Merighi A; Corbascio D; Rottigni V; Fistetto G; Esposito A
Eur Rev Med Pharmacol Sci; 2013 Dec; 17(24):3272-8. PubMed ID: 24379055
[TBL] [Abstract][Full Text] [Related]
30. Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: A systematic review.
Miyazaki H; Igarashi A; Takeuchi T; Teng L; Uda A; Deguchi H; Higuchi K; Tango T
J Gastroenterol Hepatol; 2019 Aug; 34(8):1316-1328. PubMed ID: 30883868
[TBL] [Abstract][Full Text] [Related]
31. A review of pharmacotherapy for treating gastroesophageal reflux disease (GERD).
Savarino E; Zentilin P; Marabotto E; Bodini G; Della Coletta M; Frazzoni M; de Bortoli N; Martinucci I; Tolone S; Pellegatta G; Savarino V
Expert Opin Pharmacother; 2017 Sep; 18(13):1333-1343. PubMed ID: 28754071
[TBL] [Abstract][Full Text] [Related]
32. Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors.
Koek GH; Sifrim D; Lerut T; Janssens J; Tack J
Gut; 2003 Oct; 52(10):1397-402. PubMed ID: 12970129
[TBL] [Abstract][Full Text] [Related]
33. Emerging drugs for gastroesophageal reflux disease.
Boeckxstaens GE
Expert Opin Emerg Drugs; 2009 Sep; 14(3):481-91. PubMed ID: 19650746
[TBL] [Abstract][Full Text] [Related]
34. PPI therapy is equally effective in well-defined non-erosive reflux disease and in reflux esophagitis: a meta-analysis.
Weijenborg PW; Cremonini F; Smout AJ; Bredenoord AJ
Neurogastroenterol Motil; 2012 Aug; 24(8):747-57, e350. PubMed ID: 22309489
[TBL] [Abstract][Full Text] [Related]
35. Positive predictors for gastroesophageal reflux disease and the therapeutic response to proton-pump inhibitors.
Becker V; Grotz S; Schlag C; Nennstiel S; Beitz A; Haller B; Schmid RM; Meining A; Bajbouj M
World J Gastroenterol; 2014 Apr; 20(14):4017-24. PubMed ID: 24744591
[TBL] [Abstract][Full Text] [Related]
36. Vonoprazan causes symptomatic improvement in non-erosive gastroesophageal reflux disease: A systematic review and meta-analysis.
Bandyopadhyay S; Verma P; Samajdar SS; Das S
Clin Res Hepatol Gastroenterol; 2024 Jun; 48(6):102373. PubMed ID: 38719148
[TBL] [Abstract][Full Text] [Related]
37. Long-term benefit of transoral incisionless fundoplication using the esophyx device for the management of gastroesophageal reflux disease responsive to medical therapy.
Stefanidis G; Viazis N; Kotsikoros N; Tsoukalas N; Lala E; Theocharis L; Fassaris A; Manolakopoulos S
Dis Esophagus; 2017 Feb; 30(3):1-8. PubMed ID: 27868281
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of Vonoprazan, a Novel Potassium-Competitive Acid Blocker, in Patients with Proton Pump Inhibitor-Refractory Acid Reflux.
Akiyama J; Hosaka H; Kuribayashi S; Moriyasu S; Hisada Y; Okubo H; Watanabe K; Imbe K; Nagata N; Kojima Y; Yokoi C; Uemura N; Shimoyama Y; Kawamura O; Yamada M; Kusano M
Digestion; 2020; 101(2):174-183. PubMed ID: 30897577
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness and safety of proton pump inhibitors in infantile gastroesophageal reflux disease.
Higginbotham TW
Ann Pharmacother; 2010 Mar; 44(3):572-6. PubMed ID: 20124466
[TBL] [Abstract][Full Text] [Related]
40. ARE THE PERSISTENT SYMPTOMS TO PROTON PUMP INHIBITOR THERAPY DUE TO REFRACTORY GASTROESOPHAGEAL REFLUX DISEASE OR TO OTHER DISORDERS?
Azzam RS
Arq Gastroenterol; 2018 Nov; 55Suppl 1(Suppl 1):85-91. PubMed ID: 30304291
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
